ClinicalTrials.gg
RecruitingNCT02986087FETOUpdated May 11, 2025

Feto-Endoscopic Tracheal Occlusion (FETO) for Severe Congenital Diaphragmatic Hernia

An interventional study of Fetal Tracheal Occlusion in Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia and Pulmonary; Hypertension, sponsored by Children's Hospital Medical Center, Cincinnati. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-11.

Sponsored by Children's Hospital Medical Center, Cincinnati · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Nov 2016; still recruiting 10 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-14

Among 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States — 24 open to participants now, 28 under way, 2 of them phase 3. Hernias, Diaphragmatic, Congenital · United States.

Planned enrollment
13th of 36
40 · median 21
Started
2016
the only one that year
No phase
28 of 45
18 open now
Primary completion
2025-12
later than 3 of 27 live
Registered
16th of 45
by date
Lead sponsor
2 of 45
Children's Hospital Medical Center, Cincinnati

Among the 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States, this one is the 13th largest by planned enrollment of the 36 interventional ones that give a count, is the only one that started in 2016, is one of 28 with no phase, reaches primary completion later than 3 of the 27 other live ones, and was the 16th registered.

Hernias, Diaphragmatic, Congenital

86 studies on the registry are indexed under Hernias, Diaphragmatic, Congenital; 39 are open to participants now.

Browse Hernias, Diaphragmatic, Congenital studies →

Open to participants now

24 of the 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 32 Hernias, Diaphragmatic, Congenital studies recruiting now, 16 (50%) set no upper age limit and 16 (50%) stop at 75 or younger; 13 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 50 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States, or all of them as a file.
02

Study summary

Tracheal occlusion IDE approved by FDA for congenital diaphragmatic hernia fetuses.

Read the detailed description

Fetuses with congenital diaphragmatic hernia with liver-up, and an observed to expected lung-to-head ratio of \<25%, LHR \<1, or a moderate category with o/e LHR \<30%, singleton pregnancy, no known other anomalies, gestational age \< 29 weeks 6 days (severe), gestational age \< 31 weeks 6 days (moderate), no maternal disease, maternal age > 18 years old.... meet criteria to be offered fetal tracheal occlusion. We want to test feasibility and efficacy in our center.

03

Conditions studied

  • Congenital Diaphragmatic Hernia
  • Pulmonary Hypoplasia
  • Pulmonary; Hypertension
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Isolated CDH with liver up
  • Severe pulmonary hypoplasia with ultrasound O/E LHR \<25% at the time of surgery
  • Gestational age at FETO procedure 27 weeks 0 days to 29 weeks 6 days
  • Moderate pulmonary hypoplasia with ultrasound O/E LHR \<30% and liver-up at the time of surgery
  • Gestational age at FETO procedure 30 weeks 0 days to 31 weeks 6 days in this moderate category
  • Maternal age greater than or equal to 18 years
  • Gestational age at enrollment prior to 29 weeks 6 days, or 31 weeks 6 days in moderate category
  • Normal karyotype or FISH
  • Normal fetal echocardiogram
  • Singleton pregnancy
  • Willing to remain in the greater Cincinnati area for remainder of pregnancy
  • Family considered and decline option of termination of the pregnancy at less than 24 weeks 0 days
  • Family meets psychosocial criteria

Exclusion criteria

Exclusion Criteria:

  • Patient \< 18 years old
  • Multi-fetal pregnancy
  • Rubber latex allergy
  • Preterm labor, cervix shortened (\<15 mm) or uterine anomaly strongly predisposing to preterm labor, placenta previa
  • Bilateral CDH, isolated left sided CDH with an O/E > 30%
  • Additional fetal anomaly by ultrasound, MRI, or echocardiogram
  • Chromosomal abnormalities
  • Maternal to fetoscopic surgery or severe maternal condition in pregnancy
  • Incompetent cervix with or without a cerclage
  • Placental abnormalities known at time of enrollment
  • Maternal , Hepatits B,
  • Maternal uterine anomaly
  • No safe or technically feasible fetoscopic approach to balloon placement
  • Participation in another intervention study that influences maternal and fetal morbidity and mortality or participation in this trial in a previous pregnancy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Fetal Tracheal Occlusion

    Fetuses with severe or moderate congenital diaphragmatic hernia will be offered fetal tracheal occlusion to increase lung growth.

    Device: Fetal Tracheal Occlusion

Interventions

  • DeviceFetal Tracheal Occlusion

    Fetuses with congenital diaphragmatic hernia with an observed to expected lung-to-head ratio of \<25%, LHR \<1, o/e LHR\<30% (moderate), singleton pregnancy, no known other anomalies, gestational age \< 29 weeks 6 days, no maternal disease, maternal age \> 18 years old meet criteria to be offered tracheal occlusion. We want to test feasibility and efficacy in our center.

    Also known as: FETO, Fetal Endoluminal Tracheal Occlusion

06

What researchers measure

Primary outcomes

  1. Change lung growth on prenatal imaging

    Change in o/eLHR and other prenatal imaging tests

    Time frame: prenatal period up to 40 weeks gestation

Secondary outcomes

  1. Change survival in the severe congenital diaphragmatic hernia subgroup

    Change rate of survival

    Time frame: 6 months

  2. Change need for ECMO therapy

    Change need for ECMO therapy

    Time frame: 6 months

  3. Change pulmonary hypertension

    Change pulmonary hypertension

    Time frame: 6 months

  4. Change neonatal morbidity

    Change neonatal morbidity

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2016 (actual). Primary completion is estimated for Dec 2025, 109 months after the start.

Of 40 interventional studies with no phase under Hernias, Diaphragmatic, Congenital, half reached primary completion within 108 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 133. This study's planned 109 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2016
First posted
Dec 8, 2016
StartActual
Nov 2016
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2026
Last update
May 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02986087
Responsible party
Sponsor
First posted
Dec 8, 2016
Start date
Nov 2016
Primary completion
Dec 2025 (estimated)
Completion
Dec 2026 (estimated)
Last update
May 11, 2025

Study contacts

Foong-Yen Lim, MD
Contact
Foong-Yen.Lim@cchmc.org
(513) 636-6259
Jose Peiro, MD, PhD
Contact
Jose.Peiro@cchmc.org
(513) 803-4563
Kurt Schibler, MD
study chair · CCHMC Oversight Data Safety Monitoring Committee

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion